Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Next generation allogeneic CAR-T cell therapies
Company stage: Clinical
Diseases: acute myeloid leukaemia, B-cell acute lymphoblastic leukaemia (B-ALL), multiple myeloma, Non-Hodgkin's lymphoma
Genome editing technology: TALEN
Funding stage: Public (NASDAQ:CLLS)
Location: Paris, France and New York, USA
Cellectis develops next generation allogeneic CAR-T cell therapies using its proprietary Transcription activator-like effector nuclease (TALEN) technology. The company has multiple clinical assets currently in Phase 1/2 dose escalation and dose expansion studies. The initial focus is on different types of haematological cancers, such as Non-Hodgkin's lymphoma and leukaemia. The company has licensed the TALEN technology to multiple other companies working with cellular therapies.